BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 3042243)

  • 1. Pharmacokinetics of calcium antagonists under development.
    Abernethy DR; Schwartz JB
    Clin Pharmacokinet; 1988 Jul; 15(1):1-14. PubMed ID: 3042243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists].
    Rameis H
    Wien Med Wochenschr; 1993; 143(19-20):490-500. PubMed ID: 8135031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective pharmacokinetics of dihydropyridine calcium antagonists.
    Tokuma Y; Noguchi H
    J Chromatogr A; 1995 Mar; 694(1):181-93. PubMed ID: 7719464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol alters the binding of Ca2+ channel blockers to the membrane lipid bilayer.
    Mason RP; Moisey DM; Shajenko L
    Mol Pharmacol; 1992 Feb; 41(2):315-21. PubMed ID: 1531693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.
    Echizen H; Eichelbaum M
    Clin Pharmacokinet; 1986; 11(6):425-49. PubMed ID: 3542336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.
    Opie LH
    Cardiovasc Drugs Ther; 1988 Mar; 1(6):625-56. PubMed ID: 3154329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium antagonists. Pharmacokinetic properties.
    Kates RE
    Drugs; 1983 Feb; 25(2):113-24. PubMed ID: 6339196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetic profile of amlodipine.
    Abernethy DR
    Am Heart J; 1989 Nov; 118(5 Pt 2):1100-3. PubMed ID: 2530866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.
    Freedman DD; Waters DD
    Drugs; 1987 Nov; 34(5):578-98. PubMed ID: 3319491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of vasodilators. Part I.
    Kirsten R; Nelson K; Kirsten D; Heintz B
    Clin Pharmacokinet; 1998 Jun; 34(6):457-82. PubMed ID: 9646008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of calcium antagonists. An update.
    Kelly JG; O'Malley K
    Clin Pharmacokinet; 1992 Jun; 22(6):416-33. PubMed ID: 1587055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similarities and differences between calcium antagonists: pharmacological aspects.
    van Zwieten PA; Pfaffendorf M
    J Hypertens Suppl; 1993 Mar; 11(1):S3-11. PubMed ID: 8483019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II).
    Onoda JM; Nelson KK; Taylor JD; Honn KV
    Cancer Res; 1989 Jun; 49(11):2844-50. PubMed ID: 2720644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist.
    Klotz U
    Arzneimittelforschung; 2002; 52(3):155-61. PubMed ID: 11963641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium channel antagonists. Part V: Second-generation agents.
    Opie LH
    Cardiovasc Drugs Ther; 1988 Jul; 2(2):191-203. PubMed ID: 3154705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency- and potential-dependency of the negative inotropic action of various dihydropyridine and non-dihydropyridine calcium antagonists.
    Herzig S; Lüllmann H; Sieg H
    Pharmacol Toxicol; 1992 Sep; 71(3 Pt 1):229-35. PubMed ID: 1438049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist.
    Abernethy DR
    J Cardiovasc Pharmacol; 1991; 17 Suppl 1():S4-7. PubMed ID: 16296697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics and pharmacodynamics of calcium channel blockers].
    Mayer O
    Vnitr Lek; 1995 Mar; 41(3):164-6. PubMed ID: 7762170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
    Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
    Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between digoxin and the calcium antagonists nicardipine and tiapamil.
    Lessem J; Bellinetto A
    Clin Ther; 1983; 5(6):595-602. PubMed ID: 6627286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.